Cancer Biology

Subtypes and proliferation patterns of small intestine neuroendocrine tumors revealed by single-cell RNA sequencing

1. Einav Somech
2. Debdatta Halder
3. Avishay Spitzer
4. Chaya Barbolin
5. Michael Tyler
6. Reut Halperin
7. Moshe Biton
8. Amit Tirosh
9. Itay Tirosh

• Curated by eLife

  eLife Assessment

  This is a valuable study that uses single-cell RNA sequencing to define tumor-intrinsic transcriptional programs that characterize distinct types of small intestine neuroendocrine tumors. The evidence supporting the claims of the authors is solid, but would benefit from a larger sample size. The work will be of interest to cancer biologists studying neuroendocrine tumors, as well as those studying tumor heterogeneity more broadly.

Reviewed by eLife

The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells

1. Haibin Liu
2. Lulu Yu
3. Vladimir Majerciak
4. Thomas J Meyer
5. Ming Yi
6. Peter F Johnson
7. Maggie Cam
8. Douglas R Lowy
9. Zhi-Ming Zheng

• Curated by eLife

  eLife Assessment

  This study reports important new insights into the roles of a long noncoding RNA, lnc-FANCI-2, in the progression of cervical cancer induced by a type of human papillomavirus. Through a blend of cell biological, biochemical, and genetic analyses of RNA and protein expression, protein-protein interaction, cell signaling, and cell morphology, the authors provide convincing evidence that lnc-FANCI-2 affects cervical cancer outcome by regulating the RAS signaling pathway. These findings will be of interest to scientists in the fields of cervical cancer, long noncoding RNA, and cell signaling.

Reviewed by eLife

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

1. Veera K. Ojala
2. Sini Ahonen
3. Sara Peltola
4. Aura Tuohisto‐Kokko
5. Olaya Esparta
6. Peppi Suominen
7. Anne Jokilammi
8. Iman Farahani
9. Deepankar Chakroborty
10. Nikol Dibus
11. Steffen Boettcher
12. Tomi T. Airenne
13. Mark S. Johnson
14. Lisa D. Eli
15. Klaus Elenius
16. Kari J. Kurppa

Reviewed by Review Commons

Tumoral CD24 tunes platelets binding and pro-metastatic functions

1. Vincent Mittelheisser
2. Cristina Liboni
3. Clarisse Mouriaux
4. Silvia Maria Grazia Trivigno
5. Louis Bochler
6. Maria Garcia-Leon
7. Annabel Larnicol
8. Laetitia Paulen
9. Tristan Stemmelen
10. Pierre Henri Mangin
11. Olivier Lefebvre
12. Jacky G. GOETZ

Reviewed by preLights

PA28γ promotes the malignant progression of tumor by elevating mitochondrial function via C1QBP

1. Jiongke Wang
2. Yujie Shi
3. Ying Wang
4. Yingqiang Shen
5. Huan Liu
6. Silu Sun
7. Yimei Wang
8. Xikun Zhou
9. Yu Zhou
10. Xin Zeng
11. Jing Li
12. Qianming Chen

• Curated by eLife

  eLife Assessment

  This manuscript determines how PA28g, a proteasome regulator that is overexpressed in tumors, and C1QBP, a mitochondrial protein for maintaining oxidative phosphorylation that plays a role in tumor progression, interact in tumor cells to promote their growth, migration and invasion. Additional experiments and analyses that supported the theoretical models for the interaction have been performed in response to the reviews. The overall findings and conceptual framework are important and the evidence is solid. A logical extrapolation of this work is to test the C1QBP mutants using functional assays to determine whether the mutations can decrease the protein stability mediated by the interaction with PA28g.

Reviewed by eLife

PRMT1-mediated metabolic reprogramming promotes leukemogenesis

1. Hairui Su
2. Yong Sun
3. Han Guo
4. Chiao-Wang Sun
5. Qiuying Chen
6. Szumam Liu
7. Anlun Li
8. Min Gao
9. Rui Zhao
10. Glen Raffel
11. Jian Jin
12. Cheng-Kui Qu
13. Michael Yu
14. Christopher A Klug
15. George Y Zheng
16. Scott Ballinger
17. Matthew Kutny
18. Long X Zheng
19. Zechen Chong
20. Chamara Senevirathne
21. Steven Gross
22. Yabing Chen
23. Minkui Luo
24. Xinyang Zhao

• Curated by eLife

  eLife Assessment

  This study reveals that PRMT1 overexpression drives tumorigenesis of acute megakaryocytic leukemia (AMKL) and that targeting PRMT1 is a viable approach for treating AMKL. After revision, both reviewers found that these findings are important and that the data supporting these findings are convincing. Furthermore, these findings likely have significant implications for the treatment of AMKL with PRMT1 overexpression in the future.

Reviewed by eLife

Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition

1. Laleh S Arabanian
2. Jenni Adamsson
3. Anke Unger
4. Raffaella Di Lucrezia
5. Tim Bergbrede
6. Arghavan Ashouri
7. Erik Larsson
8. Peter Nussbaumer
9. Bert M Klebl
10. Lars Palmqvist
11. Claes M Gustafsson

• Curated by eLife

  eLife Assessment

  This solid study assesses a mitochondrial polymerase inhibitor in combination with the BCL-2 inhibitor venetoclax, with the aim to increase the elimination of acute myeloid leukemia. It provides valuable findings of combinatorial efficacy using preclinical models in vitro and in vivo, confirming the overall importance of targeting oxidative phosphorylation to overcome venetoclax resistance in acute myeloid leukemia, and could be strengthened through mechanistic studies demonstrating on target effects and pharmacodynamic efficacy in vivo. The study is of interest to hematologists because it addresses a key biomedical issue in acute myeloid leukemia (venetoclax resistance) and provides data regarding the safety and activity of a novel inhibitor of the mitochondrial polymerase in combination with venetoclax.

Reviewed by eLife

NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer

1. Shengsheng Zhao
2. Ji Lin
3. Bingzi Zhu
4. Yin Jin
5. Qiantong Dong
6. Xiaojiao Ruan
7. Dan Jin
8. Yongdong Yi
9. Binglong Bai
10. Hongzheng Li
11. Danna Liang
12. Jianhua Lu
13. Letian Meng
14. Xiang Wang
15. Yuekai Cui
16. Yuyang Gu
17. Xian Shen
18. Xufeng Lu
19. Shangrui Rao
20. Weijian Sun

• Curated by eLife

  eLife Assessment

  This fundamental study identified a novel role of NOLC1 in regulating p53 nuclear transcriptional activity and p53-mediated ferroptosis in gastric cancer. After major revisions, the evidence supporting the conclusions is solid. However, some new experiments are needed to draw more robust conclusions regarding the ferroptosis-associated studies.

Reviewed by eLife

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

1. Aamena Y. Patel
2. Peyman Zarrineh
3. Nathnael T. Tuffa
4. Jigar H. Sheth
5. Sumitra Mohan
6. Mudassar Iqbal
7. Sankari Nagarajan

Reviewed by Review Commons

Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation

1. Jennifer J Twardowski
2. Thomas I Heist
3. Zamira Guerra Soares
4. Emily S Berry
5. Luis I Ruffolo
6. Christoph Pröschel
7. Stephano S Mello

Reviewed by Review Commons